Background: Reviewing and analyzing the Clinico-pathologic aspects of non-melanoma skin cancer of the head and neck (NMSCHN), type of management, prognostic factors, and disease-free survival (DFS) in a period of 5 ye...Background: Reviewing and analyzing the Clinico-pathologic aspects of non-melanoma skin cancer of the head and neck (NMSCHN), type of management, prognostic factors, and disease-free survival (DFS) in a period of 5 years at the National Cancer Institute—Cairo University—Egypt. Materials and Methods: A retrospective study of two hundred patients with NMSCHN was treated at the National Cancer Institute—Cairo University—Egypt from January 2008 to December 2012. The mean follow-up was 6 months (1 - 84 months). Results: 117 males and 83 females with 90% ≥ 50 years old. The scalp (27.5%), the periorbital region (13%), the cheek (12.5%) and the nose (12.5%) are the main anatomical sites affected. BCC represented 71.5% with nodular type (79%) predominance;SCC represented 21% with GII (61.1%) the commonest grade. Surgery was the main modality of treatment (93%) with local flaps only (63.9%) and primary closure (14.7%) were the main surgical options following wide local excision. Positive and close margins were detected in 23.5% of excised specimens. No significant association was found between disease-free survival (DFS) and pathology, treatment modality, the occurrence of complications or safety margin status. Conclusion: NMSCHN lesions should be surgically excised in specialized high volume centers with readily available peripheral margin control and should be operated by senior experienced surgeons.展开更多
<strong>Background:</strong><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;"> There is ample evidence...<strong>Background:</strong><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;"> There is ample evidence to support the safety and efficacy of the topical anticancer cream Curaderm in the treatment of non-melanoma skin cancers. Curaderm contains the natural glycoalkaloid solamargine in the form of BEC, which has been established as a novel antineoplastic agent. BEC is the initials of the inventor of the described technology. It is known that BEC expresses anti-melanoma properties in cell culture and animals. Because of potential metastasis, clinical work with BEC on melanoma was stalled. However, recent studies show that BEC has anti-metastatic properties and this, together with currently better understanding of the mode of anti-cancer actions of BEC</span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">,</span></span></span><span><span><span style="font-family:""><span style="font-family:Verdana;"> has led to the treatment of a patient who refused to have surgery for her clinically diagnosed stage II melanoma. </span><b><span style="font-family:Verdana;">Treatment: </span></b><span style="font-family:Verdana;">A 67-year woman had a birthmark that developed into a clinically diagnosed stage II melanoma and was treated with topical application of Curaderm twice daily for 7 weeks. </span><b><span style="font-family:Verdana;">Results:</span></b><span style="font-family:Verdana;"> The pattern of response of the melanoma to Curaderm therapy was similar to that observed when basal cell carcinoma is treated with Curaderm. The melanoma responded rapidly to the treatment and in 7 weeks the lesion was removed with no demonstrable side effects. The cosmetic end result was very acceptable. </span><b><span style="font-family:Verdana;">Conclusion:</span></b><span style="font-family:Verdana;"> The clinical resolution of the melanoma with Curaderm pharmacotherapy conforms to the cell culture and animal observations that solasodine rhamnosides, and thus Curaderm, is very specific and efficacious for the first in man treatment of melanoma, creating the possibility of a simple treatment for melanoma. Further investigations with controlled clinical trials are warranted.</span></span></span></span>展开更多
Non-melanoma skin cancer(NMSC) is one of the most common cancers in the US, although the role of obesity in skin cancer remains unclear. In vivo studies have consistently demonstrated that obese mice challenged with U...Non-melanoma skin cancer(NMSC) is one of the most common cancers in the US, although the role of obesity in skin cancer remains unclear. In vivo studies have consistently demonstrated that obese mice challenged with UVB radiation show increased skin tumorigenesis in comparison with leaner control mice. Growing evidence suggests that enhanced inflammation, oxidative stress and impaired apoptosis may play important roles in the development of skin cancer. Interventions such as voluntary exercise and the surgical removal of parametrial fat have been demonstrated to be effective in reducing adipose tissue that may influence the development of skin cancer; however, these interventions are not achievable in all obese patients. Therefore, the use of dietary natural phytochemicals that may modify and reverse the deregulated molecular and epigenetic events related to obesity and cancer development might represent a potential therapeutic modality due to their potential efficacy and low toxicity. In this review, we aim to provide the molecular and epigenetic basis of the NMSC-obesity relationship and to highlight the potential anti-cancer chemopreventive benefits of dietary phytochemicals such as sulforaphane and epigallocatechin-3-gallate.展开更多
目的评价细胞色素P450酶CYP1A1基因MSP1、IIe-Val多态性与非黑色素性皮肤癌易感性的关系。方法检索Pubmed，embase，Cohrance，CNKI、维普、万方学位论文全文数据库、中国生物医学文献数据库平台，查找文献从建库到2015年10月。采用RevM...目的评价细胞色素P450酶CYP1A1基因MSP1、IIe-Val多态性与非黑色素性皮肤癌易感性的关系。方法检索Pubmed，embase，Cohrance，CNKI、维普、万方学位论文全文数据库、中国生物医学文献数据库平台，查找文献从建库到2015年10月。采用RevMan5．0．0软件进行Meta分析。结果最终纳入3篇文献，Meta分析见CYP1A1基因IIe-Val位点多态性等位基因IIe和Val与非黑色素性皮肤癌易感性有显著关联（IIe vs Val：OR=0．56，95％CI=0．37～0．85，P=0．007），未见CYP1A1基因MSP1多态性与非黑色素性皮肤癌易感性相关。结论CYP1A1基因IIe-Val多态性与非黑色素性皮肤癌相关，携带等位基因Val可增加非黑色素性皮肤癌发病率。展开更多
文摘Background: Reviewing and analyzing the Clinico-pathologic aspects of non-melanoma skin cancer of the head and neck (NMSCHN), type of management, prognostic factors, and disease-free survival (DFS) in a period of 5 years at the National Cancer Institute—Cairo University—Egypt. Materials and Methods: A retrospective study of two hundred patients with NMSCHN was treated at the National Cancer Institute—Cairo University—Egypt from January 2008 to December 2012. The mean follow-up was 6 months (1 - 84 months). Results: 117 males and 83 females with 90% ≥ 50 years old. The scalp (27.5%), the periorbital region (13%), the cheek (12.5%) and the nose (12.5%) are the main anatomical sites affected. BCC represented 71.5% with nodular type (79%) predominance;SCC represented 21% with GII (61.1%) the commonest grade. Surgery was the main modality of treatment (93%) with local flaps only (63.9%) and primary closure (14.7%) were the main surgical options following wide local excision. Positive and close margins were detected in 23.5% of excised specimens. No significant association was found between disease-free survival (DFS) and pathology, treatment modality, the occurrence of complications or safety margin status. Conclusion: NMSCHN lesions should be surgically excised in specialized high volume centers with readily available peripheral margin control and should be operated by senior experienced surgeons.
文摘<strong>Background:</strong><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;"> There is ample evidence to support the safety and efficacy of the topical anticancer cream Curaderm in the treatment of non-melanoma skin cancers. Curaderm contains the natural glycoalkaloid solamargine in the form of BEC, which has been established as a novel antineoplastic agent. BEC is the initials of the inventor of the described technology. It is known that BEC expresses anti-melanoma properties in cell culture and animals. Because of potential metastasis, clinical work with BEC on melanoma was stalled. However, recent studies show that BEC has anti-metastatic properties and this, together with currently better understanding of the mode of anti-cancer actions of BEC</span></span></span><span style="font-family:Verdana;"><span style="font-family:Verdana;"><span style="font-family:Verdana;">,</span></span></span><span><span><span style="font-family:""><span style="font-family:Verdana;"> has led to the treatment of a patient who refused to have surgery for her clinically diagnosed stage II melanoma. </span><b><span style="font-family:Verdana;">Treatment: </span></b><span style="font-family:Verdana;">A 67-year woman had a birthmark that developed into a clinically diagnosed stage II melanoma and was treated with topical application of Curaderm twice daily for 7 weeks. </span><b><span style="font-family:Verdana;">Results:</span></b><span style="font-family:Verdana;"> The pattern of response of the melanoma to Curaderm therapy was similar to that observed when basal cell carcinoma is treated with Curaderm. The melanoma responded rapidly to the treatment and in 7 weeks the lesion was removed with no demonstrable side effects. The cosmetic end result was very acceptable. </span><b><span style="font-family:Verdana;">Conclusion:</span></b><span style="font-family:Verdana;"> The clinical resolution of the melanoma with Curaderm pharmacotherapy conforms to the cell culture and animal observations that solasodine rhamnosides, and thus Curaderm, is very specific and efficacious for the first in man treatment of melanoma, creating the possibility of a simple treatment for melanoma. Further investigations with controlled clinical trials are warranted.</span></span></span></span>
基金Institutional funds,R01-CA118947 and R01-CA152826 from the National Cancer Institute(NCI)R01AT007065 from the National Center for Complementary and Alternative Medicines(NCCAM)and the Office of Dietary Supplements(ODS)
文摘Non-melanoma skin cancer(NMSC) is one of the most common cancers in the US, although the role of obesity in skin cancer remains unclear. In vivo studies have consistently demonstrated that obese mice challenged with UVB radiation show increased skin tumorigenesis in comparison with leaner control mice. Growing evidence suggests that enhanced inflammation, oxidative stress and impaired apoptosis may play important roles in the development of skin cancer. Interventions such as voluntary exercise and the surgical removal of parametrial fat have been demonstrated to be effective in reducing adipose tissue that may influence the development of skin cancer; however, these interventions are not achievable in all obese patients. Therefore, the use of dietary natural phytochemicals that may modify and reverse the deregulated molecular and epigenetic events related to obesity and cancer development might represent a potential therapeutic modality due to their potential efficacy and low toxicity. In this review, we aim to provide the molecular and epigenetic basis of the NMSC-obesity relationship and to highlight the potential anti-cancer chemopreventive benefits of dietary phytochemicals such as sulforaphane and epigallocatechin-3-gallate.
文摘目的评价细胞色素P450酶CYP1A1基因MSP1、IIe-Val多态性与非黑色素性皮肤癌易感性的关系。方法检索Pubmed，embase，Cohrance，CNKI、维普、万方学位论文全文数据库、中国生物医学文献数据库平台，查找文献从建库到2015年10月。采用RevMan5．0．0软件进行Meta分析。结果最终纳入3篇文献，Meta分析见CYP1A1基因IIe-Val位点多态性等位基因IIe和Val与非黑色素性皮肤癌易感性有显著关联（IIe vs Val：OR=0．56，95％CI=0．37～0．85，P=0．007），未见CYP1A1基因MSP1多态性与非黑色素性皮肤癌易感性相关。结论CYP1A1基因IIe-Val多态性与非黑色素性皮肤癌相关，携带等位基因Val可增加非黑色素性皮肤癌发病率。
